NICE spurns Lilly’s breast cancer drug Verzenio in favor of rivals from Pfizer and Novartisspir

Lilly's Verzenio for hormone receptor-positive, HER2-negative breast cancer seems to work just as well as Pfizer’s Ibrance and Novartis’ Kisqali, England's drug-price watchdog said, but Lilly didn't make a plausible case that it's more cost-effective.